KOO - HL has the rights for China, Hong Kong and Macau, that is what they negotiated when they put their first chunk of money into RVX. Last fall they put up $8 million for a Right of First Refusal to sell apabetalone in the USA. This RFR gives HL nothing but a RFR. If any BP that may want to have world wide rights, outside of China, they simply enter a bidding war for the USA territory. If it is determined that world wide annual sales, outside of China is expected to be say $15 billion and USA sales are expected to be 50% of worldwide sales then in theory apabetalone should be worth 1Xs annual sales or $15 billion and the USA market would represent $7.5 billion of that total. At that point HL either comes up with $7.5 billion or gets their $8 million back. Keep in mind that this RFR is actually a very positive tool for both RVX and HL. The leverage that exists because of this RFR serves both RVX and HL as they own a big chunk of RVX. HL wins either way and the shareholders win either way. The China territory is not even part of the discussions unless there is a separate deal between HL and an interested BP but any deal for the China territories will not affect the RVX share price in theory as RVX gave that up years ago for the cash HL put into the company.

The Medison Company deal is another story. This drug broker gives there clients, both the manufacturers and hospitals/clinics the greatest representation in this tiny market. That market is less than .1% of the world wide market. It may be in any BPs best interest to use this relationship rather than their inhouse sales force in that tiny market in any event as they have this great representation.

More regional deals could present some additional issues going forward which is why RVX may not have gone forward with one so far.

The Investment Bankers that negotiate these deals are very good at what they do and get paid handsomely for their skills. I have not seen anything so far that would seem to be a deal breaker. To the contrary the HL and MC deals look to be beneficial to deal making IMO.

All IMO, dyodd.

tada